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Summary Aminoglutethimide has been used in combination with hydrocortisone in patients with advanced
prostatic cancer with the rationale that it causes a 'medical adrenalectomy'. Both objective and subjective
responses have been recorded. We have examined the effect of AG and HC alone and in combination on
plasma androgen levels throughout the day in two studies on 11 such patients. Whilst AG combined with HC
led to a significant suppression of both testosterone and androstenedione levels, the suppression with HC
alone was significantly greater, indicating that any beneficial clinical effects of AG in these patients is not due
to its suppression of adrenal androgen secretion.
First-line therapy for patients with advanced prostatic cancer
is surgical or medical orchiectomy. The efficacy of treatment
results from the reduction of androgenic stimulation of the
tumour, with greater than 90% fall in circulating levels of
testosterone. Testosterone is, however, still detectable in
plasma after orchiectomy as a result of its secretion from the
adrenal glands.
Second-line treatment is largely directed at opposing or
suppressing these adrenal androgens. The demonstration that
aminoglutethimide (AG) inhibited the conversion of
cholesterol to pregnenolone (Dexter et al., 1967) led to the
use of the drug in combination with hydrocortisone (HC) as
a so-called 'medical adrenalectomy' in postmenopausal
breast cancer patients (Santen et al., 1974) and also with
some apparent benefit in prostate cancer patients (Robinson
et al., 1974). The mechanism of action of this combination in
prostatic cancer has been questioned, since HC is itself an
adrenal suppressant and AG is now accepted as acting by
aromatase inhibition in breast cancer patients (Santen et al.,
1978; Stuart-Harris et al., 1984). When used alone in post-
menopausal patients AG causes an increase in androgen
levels (Harris et al., 1983a; Vermeulen et al., 1983; Stuart-
Harris et al., 1985).
In this report the results are given of two studies which
were conducted to assess the effects of AG and HC, both
alone and in combination, on androgen levels and to
determine whether these could explain the efficacy of amino-
glutethimide in prostatic cancer patients.
addition to the first four days of treatment at 0600, 0900,
1200, 1500, 1800, 2100 and 2400.
Study 2
Five patients were treated with HC, 20mg b.d. alone for 7
days and thereafter in combination with AG, 250mg b.d.
The drugs were administered at 0800 and 2000. Blood
samples were taken at 0600, 0900, 1200, 1500, 1800 and 2400
on the two days preceding treatment and on the 6th and 7th
day of receiving (i) HC alone, and (ii) the 2 drugs in
combination.
Whilst the schedule of blood sampling was adhered to as
closely as possible, in a few cases in both studies samples
were not available at all time points. Serum was stored at
-20°C until analysis for testosterone and androstenedione
by radioimmunoassay after solvent extraction and according
to previously published methodology (Harris et al., 1982;
Dowsett et al., 1984). Statistical comparisons were made
using paired and unpaired Student's t tests.
Results
Levels of testosterone and androstenedione were variable
throughout the day, both before and during treatment. A
representative profile of a patient from Study 1 is shown in
Figure 1. The changes in the levels of the two hormones
Control AG AG + HC
Patients and methods
All patients had advanced prostatic cancer and were post-
orchiectomy. None had previously received medical
endocrine therapy for their disease. The mean age of the
patients was 70 (range 59-83) and the mean time from
orchiectomy was 13.3 months (range 6-29).
Study I
Six patients were treated with AG, 250mg twice daily (b.d.),
alone for 2 days and thereafter in combination with HC,
20mg b.d. The drugs were administered at 0800 and 2000.
Blood samples were taken on the two days preceding in
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Figure 1 Levels of testosterone and androstenedione in one
patient from Study 1: AG (250mgb.d.)±HC (20mgb.d.).
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tended to parallel each other. As expected the highest and
lowest levels were generally found at 0600 and 2400
respectively, but the fall between the two time periods was
marked by additional minor peaks at various times.
The mean 24h profiles for testosterone in both studies are
shown in Figure 2. The profile for patients treated with AG
alone is very similar to that found before treatment but the
addition of HC to the AG resulted in lower mean levels of
testosterone at all time points throughout the day. Similarly
in Study 2 the levels of testosterone on AG plus HC were
lower than before treatment at all time points but were lower
still when HC was used alone. Similar 24h profiles were
found for androstenedione in both studies (not shown).
The overall mean of all values through the 24h period for
both testosterone and androstenedione before and during
each treatment is shown in Figure 3 for both studies. In
Study 1, AG alone was found to cause an overall increase in
androstenedione levels whilst AG plus HC caused significant
suppression of testosterone and androstenedione below both
their pretreatment levels and their levels during treatment
with AG alone. In Study 2 when HC was given alone a
marked and significant suppression below pretreatment levels
for testosterone and androstenedione was achieved but for
both hormones levels rose significantly on addition of AG.
For androstenedione this resulted in levels which were not
significantly different from pretreatment values, in contrast
to the suppression noted with the combined treatment in
Study 1.
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Figure 2 Mean (+s.e.) 24h profiles of testosterone in all
patients from Studies 1 and 2.
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Figure 3 Overall mean (±s.e.) levels of testosterone and
androstenedione before and during treatment in Studies 1 and 2.
A: P<O.05; AA: P<0.01.
Discussion
There are several reports of AG+ HC achieving both
objective (Worgul et al., 1983; Drago et al., 1984; Murray &
Pitt, 1984) and subjective (Robinson et al., 1974; Rostom et
al., 1982; Ponder et al., 1984) responses in advanced
prostatic cancer after relapse from first line therapy
(orchiectomy or oestrogen therapy). In addition, we (Ponder
et al., 1984) and others (Worgul et al., 1983) have
demonstrated that this regimen results in reduced plasma
androgen levels as it does in postmenopausal breast cancer
patients (Samojlik et al., 1980; Harris et al., 1984). In both
of these patient groups the adrenal glands are the major
source of circulating androgens. However, it has previously
been demonstrated that in postmenopausal patients AG
given alone results in increased plasma levels of
androstenedione and testosterone (Harris et al., 1983a;
Vermeulen et al., 1983; Stuart-Harris et al., 1985) and when
given in combination with HC results in a less extensive
suppression of the androgens than HC given alone (Harris et
al., 1984).
The results in this study indicate that the effects of AG
and HC when given alone or in combination to previously
orchiectomized prostatic cancer patients are similar to those
observed in the studies of postmenopausal women. The
increases in androgen levels observed in the latter group
during treatment with AG alone were more extensive than
those found in the prostatic cancer group, but the greater
suppression achieved by HC alone than HC in combination
with AG is as clear in the prostatic as in the breast cancer
patients. Our findings are similar to those in the recent
report of Plowman et al. (1987).
It seems likely that the increased androgen levels in
prostatic cancer patients on AG are due to inhibition of the
1lfl-hydroxylase or 21-hydroxylase enzymes as we have
previously suggested for breast cancer patients (Harris et al.,
HC 1983a). In the light of these findings, it must be concluded
that any beneficial clinical effect of AG in prostatic cancer
patients which is additional to that of HC alone is not a
result of suppression of adrenal androgen secretion and
indeed that AG is detrimental in any regimen designed to
produce this effect. It is possible that the clinical effects of
AG and HC might be due solely to HC since glucocorticoids
have been used with at least subjective benefit in post-
orchiectomy metastatic prostatic cancer (Miller & Hinman,
1954; Burt et al., 1957). However, Murray and Pitt (pers.
comm.) found in a non-randomised study that AG plus HC
was significantly more beneficial than HC alone and AG is
known to have other actions which may be of benefit to
prostatic cancer patients such as inhibition of prostaglandin
synthetase (Harris et al., 1983b), or its effects on the central
nervous system (Santen et al., 1981).
Of particular interest is the suggestion that oestrogen
suppression by aromatase inhibitors may be beneficial in
benign prostatic hypertrophy (Henderson et al., 1986).
Aromatase activity has been found to be present in
fibroblasts from prostatic tissue (Schweikert, 1979) and our
recent observation that a more specific aromatase inhibitor,
4-hydroxyandrostenedione, also leads to at least subjective
and partial objective responses in patients with advanced
post-orchiectomy prostatic cancer (unpublished results)
suggests that the aromatase inhibitory action of AG may
underlie its therapeutic activity in prostatic cancer.
The disparity between Studies 1 and 2 in the levels of
androstenedione during combination therapy appeared to be
due largely to the very high levels found in one patient at
both 6am and 6pm, that is shortly before the next doses
were administered (mean levels 11.5 and 7.9nmol l-1,
respectively). This patient also had the highest pretreatment
levels of androstenedione. The difference between the two
studies probably results from the inclusion of this patient in
Study 2 and not from the order in which treatments were
given.
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It seems clear that a randomised clinical trial is necessary
to confirm that AG plus HC is of any greater effectiveness
than HC alone in advanced prostatic cancer. Until this
question is clearly answered it will be difficult to establish if
the summation of the complex pharmacology of AG is
beneficial in prostatic cancer and which if any of its
individual activities is responsible.
We are grateful for financial support provided by Ciba-Geigy
Pharmaceuticals and for the nursing and technical assistance
provided during these studies.
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